ImmunityBio Investors File Class Action Lawsuit Over FDA Warning
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy IBRX?
Source: Globenewswire
- Class Action Notice: Investors in ImmunityBio, Inc. are reminded that those who purchased the company's securities between January 19, 2026, and March 24, 2026, must file lead plaintiff applications by May 26, 2026, to participate in the securities class action lawsuit against the company.
- FDA Warning Impact: On March 24, 2026, a warning letter from the FDA to CEO Richard Adcock highlighted misleading advertising claims regarding Anktiva, which violated the Federal Food, Drug, and Cosmetic Act, directly affecting investor confidence and raising concerns about the company's compliance.
- Significant Stock Drop: Following the FDA warning, ImmunityBio's stock price plummeted by 21%, losing $1.98 per share to close at $7.42, reflecting market apprehension regarding the company's regulatory compliance and future outlook.
- Legal Consequences: The lawsuit alleges that ImmunityBio and certain executives failed to disclose material information during the class period, violating federal securities laws, which could expose the company to substantial legal and financial risks.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.080
Low
5.00
Averages
7.33
High
9.00
Current: 7.080
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ImmunityBio Investors File Class Action Lawsuit Over FDA Warning
- Class Action Notice: Investors in ImmunityBio, Inc. are reminded that those who purchased the company's securities between January 19, 2026, and March 24, 2026, must file lead plaintiff applications by May 26, 2026, to participate in the securities class action lawsuit against the company.
- FDA Warning Impact: On March 24, 2026, a warning letter from the FDA to CEO Richard Adcock highlighted misleading advertising claims regarding Anktiva, which violated the Federal Food, Drug, and Cosmetic Act, directly affecting investor confidence and raising concerns about the company's compliance.
- Significant Stock Drop: Following the FDA warning, ImmunityBio's stock price plummeted by 21%, losing $1.98 per share to close at $7.42, reflecting market apprehension regarding the company's regulatory compliance and future outlook.
- Legal Consequences: The lawsuit alleges that ImmunityBio and certain executives failed to disclose material information during the class period, violating federal securities laws, which could expose the company to substantial legal and financial risks.
See More
ImmunityBio Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: ImmunityBio, Inc. (IBRX) is facing a class action lawsuit for securities fraud, alleging significant misstatements and omissions regarding its lead biologic product, Anktiva, during the period from January 19 to March 24, 2026, which may have resulted in investor losses.
- Stock Price Plunge: Following an FDA warning on March 24, 2026, regarding false claims about Anktiva, ImmunityBio's stock price fell by $1.98, or 21.12%, closing at $7.42 per share, indicating severe market concerns about the company's future prospects.
- Investor Action: Affected investors are encouraged to apply for lead plaintiff status by May 26, 2026, to represent other investors in the lawsuit, with Kessler Topaz Meltzer & Check, LLP offering free consultations and emphasizing no cost obligations.
- Law Firm Background: Kessler Topaz Meltzer & Check, LLP is a leading law firm specializing in securities fraud class actions, having recovered over $25 billion for clients and represented major institutional investors, showcasing its significant influence and expertise in securities litigation.
See More
ImmunityBio Securities Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased ImmunityBio securities between January 19 and March 24, 2026, to apply as lead plaintiffs by May 26, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no upfront costs, as the law firm operates on a contingency fee basis, allowing investors to pursue claims without additional financial burden.
- Case Background: The lawsuit alleges that ImmunityBio made false or misleading statements during the class period, resulting in investor losses when the truth emerged, highlighting significant implications for the company's operations and prospects.
- Law Firm Credentials: Rosen Law Firm is renowned for its success in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
See More
ImmunityBio Faces Securities Class Action Lawsuit Over Misleading Claims
- Lawsuit Background: ImmunityBio is facing a securities class action lawsuit due to misleading claims made by its Chief Scientific Officer regarding Anktiva's efficacy, involving investors who purchased shares between January 19 and March 24, 2026, highlighting potential legal repercussions from improper promotional practices.
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, stating that its promotional materials mislead by suggesting Anktiva can cure all cancers, resulting in a more than 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization.
- Investor Losses: Hagens Berman is investigating whether ImmunityBio intentionally misled investors, urging those with significant losses to come forward, indicating that the legal action could have substantial implications for the company's future financial health.
- Public Health Concerns: The FDA emphasized that ImmunityBio's misleading claims not only undermine investor confidence but also pose a public health risk, as the company failed to provide complete information regarding Anktiva's FDA-approved indications, potentially leading patients to have false expectations about treatment outcomes.
See More
ImmunityBio Shareholder Class Action Filed Over Securities Misrepresentation
- Class Action Initiated: Bernstein Liebhard LLP announces a class action lawsuit on behalf of investors who purchased ImmunityBio (NASDAQ: IBRX) securities between January 19, 2026, and March 24, 2026, alleging misrepresentations regarding the capabilities of the company's lead biologic product, ANKTIVA, which may have resulted in investor losses.
- Lawsuit Details: Investors who acquired ImmunityBio securities during the specified period and suffered losses can file papers to serve as lead plaintiff by May 26, 2026, with the lead plaintiff representing the interests of other class members in the litigation.
- Fee Arrangement: All representation is on a contingency fee basis, meaning shareholders incur no fees or expenses, which lowers the barrier for investor participation and encourages more affected shareholders to join the lawsuit.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times in The National Law Journal's “Plaintiffs’ Hot List” for its success in handling hundreds of class actions, demonstrating its strong capabilities in securities litigation.
See More
Reminder of ImmunityBio Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased ImmunityBio securities between January 19 and March 24, 2026, of the important lead plaintiff deadline on May 26, 2026, allowing for potential compensation without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that executives at ImmunityBio made false statements during the class period, resulting in investor losses when the truth was revealed, highlighting significant deficiencies in the company's transparency and compliance.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its extensive experience and successful track record in handling such cases.
- Participation Instructions: Investors can join the class action by visiting the designated website or calling a toll-free number, emphasizing the importance of careful selection of legal counsel to ensure professional legal support.
See More
ImmunityBio Investors File Class Action Lawsuit Over FDA Warning
- Class Action Notice: Investors in ImmunityBio, Inc. are reminded that those who purchased the company's securities between January 19, 2026, and March 24, 2026, must file lead plaintiff applications by May 26, 2026, to participate in the securities class action lawsuit against the company.
- FDA Warning Impact: On March 24, 2026, a warning letter from the FDA to CEO Richard Adcock highlighted misleading advertising claims regarding Anktiva, which violated the Federal Food, Drug, and Cosmetic Act, directly affecting investor confidence and raising concerns about the company's compliance.
- Significant Stock Drop: Following the FDA warning, ImmunityBio's stock price plummeted by 21%, losing $1.98 per share to close at $7.42, reflecting market apprehension regarding the company's regulatory compliance and future outlook.
- Legal Consequences: The lawsuit alleges that ImmunityBio and certain executives failed to disclose material information during the class period, violating federal securities laws, which could expose the company to substantial legal and financial risks.
See More
ImmunityBio Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: ImmunityBio, Inc. (IBRX) is facing a class action lawsuit for securities fraud, alleging significant misstatements and omissions regarding its lead biologic product, Anktiva, during the period from January 19 to March 24, 2026, which may have resulted in investor losses.
- Stock Price Plunge: Following an FDA warning on March 24, 2026, regarding false claims about Anktiva, ImmunityBio's stock price fell by $1.98, or 21.12%, closing at $7.42 per share, indicating severe market concerns about the company's future prospects.
- Investor Action: Affected investors are encouraged to apply for lead plaintiff status by May 26, 2026, to represent other investors in the lawsuit, with Kessler Topaz Meltzer & Check, LLP offering free consultations and emphasizing no cost obligations.
- Law Firm Background: Kessler Topaz Meltzer & Check, LLP is a leading law firm specializing in securities fraud class actions, having recovered over $25 billion for clients and represented major institutional investors, showcasing its significant influence and expertise in securities litigation.
See More
ImmunityBio Securities Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased ImmunityBio securities between January 19 and March 24, 2026, to apply as lead plaintiffs by May 26, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no upfront costs, as the law firm operates on a contingency fee basis, allowing investors to pursue claims without additional financial burden.
- Case Background: The lawsuit alleges that ImmunityBio made false or misleading statements during the class period, resulting in investor losses when the truth emerged, highlighting significant implications for the company's operations and prospects.
- Law Firm Credentials: Rosen Law Firm is renowned for its success in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
See More
ImmunityBio Faces Securities Class Action Lawsuit Over Misleading Claims
- Lawsuit Background: ImmunityBio is facing a securities class action lawsuit due to misleading claims made by its Chief Scientific Officer regarding Anktiva's efficacy, involving investors who purchased shares between January 19 and March 24, 2026, highlighting potential legal repercussions from improper promotional practices.
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, stating that its promotional materials mislead by suggesting Anktiva can cure all cancers, resulting in a more than 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization.
- Investor Losses: Hagens Berman is investigating whether ImmunityBio intentionally misled investors, urging those with significant losses to come forward, indicating that the legal action could have substantial implications for the company's future financial health.
- Public Health Concerns: The FDA emphasized that ImmunityBio's misleading claims not only undermine investor confidence but also pose a public health risk, as the company failed to provide complete information regarding Anktiva's FDA-approved indications, potentially leading patients to have false expectations about treatment outcomes.
See More
ImmunityBio Shareholder Class Action Filed Over Securities Misrepresentation
- Class Action Initiated: Bernstein Liebhard LLP announces a class action lawsuit on behalf of investors who purchased ImmunityBio (NASDAQ: IBRX) securities between January 19, 2026, and March 24, 2026, alleging misrepresentations regarding the capabilities of the company's lead biologic product, ANKTIVA, which may have resulted in investor losses.
- Lawsuit Details: Investors who acquired ImmunityBio securities during the specified period and suffered losses can file papers to serve as lead plaintiff by May 26, 2026, with the lead plaintiff representing the interests of other class members in the litigation.
- Fee Arrangement: All representation is on a contingency fee basis, meaning shareholders incur no fees or expenses, which lowers the barrier for investor participation and encourages more affected shareholders to join the lawsuit.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times in The National Law Journal's “Plaintiffs’ Hot List” for its success in handling hundreds of class actions, demonstrating its strong capabilities in securities litigation.
See More
Reminder of ImmunityBio Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased ImmunityBio securities between January 19 and March 24, 2026, of the important lead plaintiff deadline on May 26, 2026, allowing for potential compensation without any out-of-pocket fees.
- Lawsuit Background: The lawsuit alleges that executives at ImmunityBio made false statements during the class period, resulting in investor losses when the truth was revealed, highlighting significant deficiencies in the company's transparency and compliance.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its extensive experience and successful track record in handling such cases.
- Participation Instructions: Investors can join the class action by visiting the designated website or calling a toll-free number, emphasizing the importance of careful selection of legal counsel to ensure professional legal support.
See More
